Clinical trials: Hepatitis C Virus
Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection
Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System
The goal of this observational study is to develop, implement, and evaluate a machine learning algorithm-based Hepatitis C Emergency Department (HepC-EnD) screening tool for use in emergency departments (EDs) to identify patients…
- Conditions
- Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection, HIV (Human Immunodeficiency Virus)
- Trial name
- HepC-EnD (NCT07406490)
- Testing
- Physician-Initiated Screening (Conventional Screening), FOCUS (Universal Screening), HepC-EnD (Targeted Screening)
- Where
- 3 sites in United States
- Volunteers
- 6,466 people, healthy volunteers welcome
- Sponsor
- University of Florida
Healthy, Hepatitis C, Chronic
A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients
A Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in HCV Genotype 1 Infected Patients
- Trial name
- NCT01523990
- Testing
- TG-2349
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Hepatitis C
The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
Clinical interventions to reduce the risk of vertical transmission of hepatitis C virus (HCV) infection from mother to infant are highly limited.
- Trial name
- TiP-HepC (NCT05368974)
- Testing
- Direct Acting Antivirals
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Task Force for Global Health
Hepatitis C
Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)
The purpose of this study is to compare the plasma pharmacokinetics (PK) of single doses of MK-3682B, a fixed dose combination (FDC) tablet containing uprifosbuvir (MK-3682) + grazoprevir (MK-5172) + ruzasvir (MK-8408) in…
- Trial name
- NCT02661126
- Testing
- MK-3682B
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus
Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691
To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of PF-04878691.
- Trial name
- NCT00810758
- Testing
- PF-04878691 3mg, PF-04878691 6mg, PF-04878691 9mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatitis C
Drug Interaction & Methadone & Buprenorphine
The purpose of this study is to assess the effects of steady state DCV/ASV/BMS-791325 fixed dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of Methadone in subjects with the stable dose of Methadone and on…
- Trial name
- NCT02045693
- Testing
- Methadone, DCV 3DAA FDC, BMS-791325
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Cervical Neoplasia, HPV Infections
Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191
Background: National Cancer Institute Protocol 04-C-N191, also known as the Costa Rica Vaccine Trial, was a double-blind controlled study of the effectiveness of an experimental human papillomavirus (HPV) vaccine in preventing…
- Trial name
- NCT01086709
- Where
- Costa Rica
- Volunteers
- 5,444 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Hepatitis C
Hepatitis C Education for Pregnant Women With Opiate Dependence - Phase 2
The goal of this study is to assess patients' attitudes and knowledge of Hepatitis C, analyze the variables that may influence patients' knowledge, and educate patients on Hepatitis C.
- Trial name
- NCT03320889
- Testing
- Educational Intervention
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- TriHealth Inc.
HIV - Human Immunodeficiency Virus, HBV (Hepatitis B Virus)
MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo
Performance study to evaluate the clinical performance of the In-Vitro Diagnostic Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and…
- Conditions
- HIV - Human Immunodeficiency Virus, HBV (Hepatitis B Virus), Hepatitis C Virus (HCV), Syphilis
- Trial name
- MAGICS MAM (NCT07388979)
- Testing
- MAGIA H3S
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Gardiens de Vies
Hepatitis C
Alcohol Use Reduction in Methadone Individuals With Hepatitis C Virus(HCV)
The Alcohol Use Reduction in Methadone Individuals with HCV was designed to compare three different types of programs for methadone maintained men and women to determine which of the three programs is most effective for:1)…
- Trial name
- NIAAA (NCT00958763)
- Testing
- Motivational Interviewing, Single - MIS, Motivational Interviewing Group, Usual Care Group - UCG
- Where
- 3 sites in United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Hepatitis C
SPC3649 Multiple Dose Study in Healthy Volunteers
The purpose of this study is to investigate the safety and tolerability of SPC3649 given in multiple doses to healthy volunteers.
- Trial name
- NCT00979927
- Testing
- SPC3649, saline
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Santaris Pharma A/S
De Novo Autoimmune Hepatitis
De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation
The purpose of this study is to provide insights into the cause, development and effects of de novo autoimmune hepatitis so that prevention and treatment strategies can be developed in order to reduce post-liver transplant…
- Trial name
- NCT02056054
- Testing
- Pediatric transplant subject with d-AIH, Pediatric transplant subject with acute rejection, Pediatric transplant subject with chronic rejection
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Yale University
Hepatitis C, Insulin Resistance
Chronic Hepatitis C and Insulin Resistance
Chronic hepatitis C (CHC) is among the commonest chronic infectious disease in Australia with >200,000 exposed persons. Amongst non-infectious chronic conditions- Type 2 diabetes, obesity and heart disease are extremely common.
- Trial name
- NCT00707603
- Where
- 2 sites in Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Garvan Institute of Medical Research
Hepatitis C Virus
Hepatitis C Virus and the Humoral Immune System
The purpose of this study is to measure specific chemokines, antibodies, and antibody-producing B cells in the blood of patients with hepatitis C virus (HCV) infection.
- Trial name
- NCT00219999
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Hepatitis C
The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients
This is an open label, dose ranging, phase1a/1b clinical trial to study the safety, Pharmacokinetics and Pharmacodynamics of Peglamda 60, 120, 180 and 240 mcg in healthy volunteers and antiviral activity of once weekly Peglamda…
- Trial name
- NCT02063607
- Testing
- Peginterferon lambda
- Where
- Vietnam
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Hepatitis C Virus
TMC435-TiDP16-C112 - Interaction Trial With Antidepressants
The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 150mg q.d. (once a day) on the steady-state pharmacokinetics of escitalopram 10 mg q.d., and vice versa.
- Trial name
- NCT01090700
- Testing
- TMC435, Escitalopram, TMC435 + Escitalopram
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV)
Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)
Evaluate the feasibility, acceptability, and usability of the intervention (primary outcomes) and coping skills and resilience (secondary outcomes) of the telehealth intervention over two months (8 weekly sessions) in a…
- Conditions
- HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV), Opioid Use Disorder
- Trial name
- NCT06799702
- Testing
- Telehealth Behavioral Intervention for promoting HIV and HCV care and MOUD among Persons who inject drugs (PWID)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Georgia
Chronic Hepatitis C
Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity
Background: According to recent estimates, the prevalence of Chronic Hepatitis C (CHC) in Canada is three times more common in First Nations (FN)and Metis compared to non-FN populations.
- Trial name
- Praire (NCT00957866)
- Testing
- Pegylated Interferons (Peg-IFN) and Ribavirin
- Where
- 3 sites in Canada
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
HIV (Human Immunodeficiency Virus), Hepatitis C
Testing of a Navigation Intervention for Hepatitis C and HIV
This study will evaluate the efficacy of navigation for hepatitis C treatment in people living with both HIV and HCV with criminal justice involvement.
- Trial name
- LINKHCV (NCT04499651)
- Testing
- Navigation
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Hepatitis C Virus
Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment
The primary objective of the study is to evaluate the single-dose pharmacokinetics (PK) of velpatasvir (formerly GS-5816) in participants with severe renal impairment using matched healthy participants as a control group.
- Trial name
- NCT02002767
- Testing
- Velpatasvir
- Where
- 5 sites in United States, New Zealand
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences